DCTH

Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology treatments. The company's primary technology is a liver-directed chemotherapy delivery system designed to administer high-dose chemotherapy directly to liver tumors while minimizing systemic exposure. Delcath has received regulatory approvals in Europe for its CHEMOSAT Delivery System for treating metastatic melanoma with liver involvement. The company continues to pursue clinical development and commercialization opportunities for its proprietary platform.